Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label IP chemotherapy. Show all posts
Showing posts with label IP chemotherapy. Show all posts
Tuesday, March 27, 2012

abstract: Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer

›
Progression-free and overall survival of a modified outpatient regime... [Gynecol Oncol. 2012] - PubMed - NCBI Abstract OBJECTIVE: G...
Tuesday, January 10, 2012

currently recruiting: Intraperitoneal Therapy For Ovarian Cancer With Carboplatin Trial - Full Text View - ClinicalTrials.gov

›
Thursday, March 17, 2011

Does intraperitoneal chemotherapy benefit optimally debulked epithelial ovarian cancer patients after neoadjuvant chemotherapy?

›
Abstract Objective To compare survival of ovarian cancer patients treated with neoadjuvant chemotherapy followed by intraperitoneal (IP) v...
Monday, October 04, 2010

The effect of age on the tolerability of intraperitoneal chemotherapy, complication rate, and survival in patients with ovarian cancer

›
Conclusions Although elderly patients appear to tolerate fewer cycles of IP chemotherapy, they do not have higher objective complication...
Saturday, February 06, 2010

Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer

›
Conclusion: Intraperitoneal chemotherapy regimens using carboplatin or cisplatin and dropping day 8 IP paclitaxel have less toxicity and le...

abstract: From randomized trial to practice: single institution experience using the GOG 172 i.p. chemotherapy regimen for ovarian cancer

›
Note : patients enrolled between January 2006 to December 2007 " Background : The objective of the study was to evaluate completion ...